| Online-Ressource |
Verfasst von: | Reck, Martin [VerfasserIn]  |
| von Pawel, J. [VerfasserIn]  |
| Zatloukal, P. [VerfasserIn]  |
| Ramlau, R. [VerfasserIn]  |
| Gorbounova, V. [VerfasserIn]  |
| Hirsh, V. [VerfasserIn]  |
| Leighl, N. [VerfasserIn]  |
| Mezger, J. [VerfasserIn]  |
| Archer, V. [VerfasserIn]  |
| Moore, N. [VerfasserIn]  |
| Manegold, Christian [VerfasserIn]  |
Titel: | Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer |
Titelzusatz: | results from a randomised phase III trial (AVAiL) |
Verf.angabe: | M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold & BO17704 Study Group |
E-Jahr: | 2010 |
Jahr: | September 2010 |
Umfang: | 6 S. |
Fussnoten: | Elektronische Reproduktion der Druckausgabe ; Gesehen am 11.05.2023 |
Titel Quelle: | Enthalten in: Annals of oncology |
Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1990 |
Jahr Quelle: | 2010 |
Band/Heft Quelle: | 21(2010), 9 vom: Sept., Seite 1804-1809 |
ISSN Quelle: | 1569-8041 |
Abstract: | Background - Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. - Patients and methods - Patients (n=1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n=345), bevacizumab 15 mg/kg (n=351) or placebo (n=347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - Results - Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64-0.87), P=0.0003 and 0.85 (0.73-1.00), P=0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78-1.11), P=0.420 and 1.03 (0.86-1.23), P=0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (∼62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - Conclusions - Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies. |
DOI: | doi:10.1093/annonc/mdq020 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1093/annonc/mdq020 |
| Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419400471 |
| DOI: https://doi.org/10.1093/annonc/mdq020 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | bevacizumab |
| chemotherapy |
| NSCLC |
| overall survival |
| vascular endothelial growth factor |
K10plus-PPN: | 184517898X |
Verknüpfungen: | → Zeitschrift |
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer / Reck, Martin [VerfasserIn]; September 2010 (Online-Ressource)